Navigation Links
Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period
Date:9/30/2010

://www.cbcbanque.be and http://www.shire.com.

Important Notice

With the exception of the CBFA, no governmental or other authority in any other jurisdiction has approved the prospectus, the tender offer or the squeeze-out. The tender offer is made only in Belgium. Neither this announcement nor the prospectus constitutes an offer to buy or to sell, or a solicitation to any person in any jurisdiction to buy or sell, any security where such an offering or solicitation is not permitted or is unlawful. No action has or will be taken outside Belgium to enable a public offer in any jurisdiction where action would be required for that purpose. Neither the prospectus, nor the acceptance forms or exercise form, or other information relevant to the tender offer in Belgium may be supplied to the public in any jurisdiction outside Belgium where a registration or other obligation may be required with regard to a public offer to buy or sell securities. Any failure to comply with these restrictions may constitute a violation of applicable financial laws and regulations in other jurisdictions. Shire explicitly declines any liability for breach of these restrictions by any person.

Notes to editors

SHIRE PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver stro
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Shire Announces Holding of 81% in Jerini AG and Publication of Offer Document
2. Change of Name to Shire plc
3. Shires New Product Portfolio Delivers Strong Quarterly Performance
4. Shire Successfully Settles Former TKT Shareholder Appraisal Rights Litigation
5. Shire plc: Change to Directors Details
6. Shire Receives FOSRENOL Paragraph IV Notice Letters from Barr Laboratories and Mylan
7. Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion
8. Shire to Enter European ADHD Market With the Acquisition of EQUASYM(R) IR and XL
9. Shire Announces Opening of Office in Japan
10. Shire Files Lawsuit Against Barr Laboratories for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patents
11. Shire Files Lawsuit Against Mylan for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014 /PRNewswire/ - iCo Therapeutics ... today reported financial results for the six months ... are expressed in Canadian dollars and presented under ... Quarter 2014 Highlights , Announced top-line ... (VA) primary endpoint for subjects enrolled in the ...
(Date:8/29/2014)... 2014 A major challenge before new ... dense realm of Boston-Cambridge, is gaining visibility that can ... Sherley, the Director of Boston’s Adult Stem Cell Technology ... national visibility of his company an important priority since ... addition to a social media marketing campaign ...
(Date:8/28/2014)... Ca. (PRWEB) August 28, 2014 Best ... rating for an alcohol-based hand sanitizer, asks food processors ... by comparing the hand sanitizer they’re currently using to ... . Hand hygiene is critical to fighting cross-contamination and ... Best Sanitizers believes there are key criteria that ...
(Date:8/28/2014)... , Aug. 28, 2014 /PRNewswire/ ... new market research report is ... Whole Exome Sequencing Market ... Preparation, Target Enrichment), by Services ... Synthesis), by Application (Cancer, Monogenic ...
Breaking Biology Technology:iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 2The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 3The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 4Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 2Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 3Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 2Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 3Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 4Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 5Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 6Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 7Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 8Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 9Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 10Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 11Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 12Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 13
... researchers at the Swedish medical university Karolinska Institutet shows ... "bad" LDL cholesterol and thereby cause an inflammation that ... T cell receptors, the researchers have managed to inhibit ... presented online in the distinguished periodical Journal of ...
... discovered that simple peptides can organize into bi-layer membranes. ... pre-biotic Earth,s chemical inventory and the organizational scaffolding essential ... form the kind of membranes needed to create long-range ... of the paper recently published by the German Chemical ...
... Conference Call on Thursday, May 6, 2010 at 4:30 p.m. Eastern Time , ... BOTHELL, WA , and VANCOUVER , May 6 /PRNewswire-FirstCall/ - OncoGenex ... three months ended March 31, 2010 and reviewed the Company,s highlights for the first quarter ... Financial Results , , , ...
Cached Biology Technology:New atherosclerosis vaccine gives promising results 2Peptides may hold 'missing link' to life 2Peptides may hold 'missing link' to life 3OncoGenex Reports First Quarter Financial Results 2OncoGenex Reports First Quarter Financial Results 3OncoGenex Reports First Quarter Financial Results 4OncoGenex Reports First Quarter Financial Results 5OncoGenex Reports First Quarter Financial Results 6OncoGenex Reports First Quarter Financial Results 7OncoGenex Reports First Quarter Financial Results 8OncoGenex Reports First Quarter Financial Results 9
(Date:8/28/2014)... PAUL (August 28, 2014) Researchers at the University ... facioscapulohumeral muscular dystrophy (FSHD) to be used for muscle ... of potential therapies for FSHD. , The research is ... Cell Reports . , There is no treatment for ... most common type of muscular dystrophy. FSHD is an ...
(Date:8/28/2014)... that could positively impact the global battle ... thanks to researchers in Penn State,s College ... made from the seaweed-derived food ingredient carrageenan ... provides a woman-initiated, drug-delivery vehicle that can ... infections during unprotected heterosexual intercourse, the researchers ...
(Date:8/28/2014)... 25 million kilometres of new roads will be built ... into Earth,s last wildernesses, where they bring an influx ... Now, an ambitious study has created a ,global roadmap, ... to balance the competing demands of development and environmental ... layer that estimates that natural importance of ecosystems and ...
Breaking Biology News(10 mins):UMN researchers find animal model for understudied type of muscular dystrophy 2Sensory-tested drug-delivery vehicle could limit spread of HIV, AIDS 2Sensory-tested drug-delivery vehicle could limit spread of HIV, AIDS 3Study shows where on the planet new roads should and should not go 2Study shows where on the planet new roads should and should not go 3
... the European Medicines Agency (EMA) approved the modified adeno-associated ... for clinical use in the Western world. uniQure, a ... treatment of a rare inherited metabolic disease called lipoprotein ... out of one million people. The disease causes severe, ...
... 2013  Paris Air Show – Marvin Test Solutions ... provider of innovative test solutions for military and commercial ... the Paris Air Show in booth 3-C82. ... longer lifecycles, industry leaders are demanding efficient, feature-rich, specialized ...
... Kingdom, the Energy Department,s National Renewable Energy Laboratory (NREL), ... paper describing a novel cellulose-degrading enzyme from a marine ... the gribble. Gribbles are biologically intriguing because ... own enzymes instead of using symbiotic microbes to break ...
Cached Biology News:No danger of cancer through gene therapy virus 2Marvin Test Solutions Demonstrates Next-Generation Armament Test Solutions at Paris Air Show 2Marvin Test Solutions Demonstrates Next-Generation Armament Test Solutions at Paris Air Show 3Novel enzyme from tiny gribble could prove a boon for biofuels research 2
...
... Human IgG Fd. ELISA Specificity: (4) ,human IgG subclass 1 ... 100% ,human IgG subclass 3 100% ,human IgG ... ... 0.04% ,human IgG Fab ...
Human VEGF R2 (KDR) MAb (Clone 89106)...
Salmonella typhimurium Immunogen: Heat inactivated bacterial cells of Salmonella typhimurium B Storage: 4 C...
Biology Products: